Research statistics
FOXO4-DRI research: publications and trials
At a glance
Publications, all years
14
Since 2017
Publications in 2026 so far
3
Through November 15, 2026
Human clinical research
0.0%
0 of 14 classified
Registered clinical trials
0
ClinicalTrials.gov
Randomized controlled trials
0
Publications reporting an RCT in people
Systematic reviews and meta-analyses
0
Preclinical studies
85.7%
8 animal · 4 in vitro · 0 computational
Records that only mention it
3
Not counted above
Status in the library: Research only. Groups: Longevity and mitochondrial peptides.
What to keep in mind
- No human clinical publication is indexed: everything published so far is preclinical, a review or commentary.
- Fewer than three randomized controlled trials are indexed.
- More than 70% of the indexed publications are animal, cell or computational studies.
- Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
Publications by year
FOXO4-DRI publications by year and evidence
Show the data
| Year | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|
| 2017 | 0 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 0 | 1 |
| 2021 | 2 | 0 | 0 | 2 |
| 2022 | 2 | 0 | 0 | 2 |
| 2023 | 1 | 0 | 0 | 1 |
| 2024 | 2 | 0 | 0 | 2 |
| 2025 | 2 | 0 | 0 | 2 |
| 2026 (to date) | 2 | 1 | 0 | 3 |
Study types
| Animal study | 8 |
|---|---|
| In vitro study | 4 |
| Editorial, letter or other | 1 |
| Review | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Longevity and aging | 8 |
|---|---|
| Tissue repair | 4 |
| Cardiovascular | 3 |
| Oncology | 3 |
| Endocrinology | 2 |
| Immune system | 2 |
| Neurological and mental health | 2 |
| Cognitive health | 1 |
| Musculoskeletal | 1 |
| Reproductive and sexual health | 1 |
Registered clinical trials
A registration is not a result.
No registered trials.
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
No human trial, systematic review or meta-analysis of FOXO4-DRI is indexed.
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.
Circulation · December 14, 2022 · Animal study · cited 145 times · open access
PMID 36515093 · DOI 10.1161/circulationaha.122.058794 · Animal studies
- Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis.
JCI insight · December 8, 2021 · Animal study · cited 119 times · open access
PMID 34877934 · DOI 10.1172/jci.insight.146334 · Animal studies
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice.
Aging · January 20, 2020 · Animal study · cited 93 times · open access
PMID 31959736 · DOI 10.18632/aging.102682 · Animal studies
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes.
Frontiers in bioengineering and biotechnology · April 29, 2021 · In vitro study · cited 55 times · open access
PMID 33996787 · DOI 10.3389/fbioe.2021.677576 · In vitro studies
- FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway.
Journal of cellular and molecular medicine · May 5, 2022 · Animal study · cited 39 times · open access
PMID 35510614 · DOI 10.1111/jcmm.17333 · Animal studies
Latest publications
- Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence.
Molecular carcinogenesis · July 2, 2026 · In vitro study · cited 0 times · open access
PMID 42391447 · DOI 10.1002/mc.70134 · In vitro studies
- Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline.
Naunyn-Schmiedeberg's archives of pharmacology · April 23, 2026 · Review · cited 2 times
PMID 42024235 · DOI 10.1007/s00210-026-05309-6 · Reviews and meta-analyses
- FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway.
Frontiers in bioengineering and biotechnology · January 15, 2026 · Animal study · cited 1 times · open access
PMID 41625068 · DOI 10.3389/fbioe.2025.1729166 · Animal studies
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.
Nature communications · July 1, 2025 · In vitro study · cited 20 times · open access
PMID 40593617 · DOI 10.1038/s41467-025-60844-9 · In vitro studies
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation.
Communications biology · February 24, 2025 · In vitro study · cited 20 times · open access
PMID 39994346 · DOI 10.1038/s42003-025-07738-0 · In vitro studies
- FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells.
Experimental gerontology · July 19, 2024 · Animal study · cited 13 times · open access
PMID 39025385 · DOI 10.1016/j.exger.2024.112522 · Animal studies
- Cellular Senescence Contributes to the Progression of Hyperoxic Bronchopulmonary Dysplasia.
American journal of respiratory cell and molecular biology · February 1, 2024 · Animal study · cited 31 times · open access
PMID 37874230 · DOI 10.1165/rcmb.2023-0038oc · Animal studies
- FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice.
Naunyn-Schmiedeberg's archives of pharmacology · April 19, 2023 · Animal study · cited 11 times
PMID 37074394 · DOI 10.1007/s00210-023-02452-2 · Animal studies
- Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.
Circulation · December 14, 2022 · Animal study · cited 145 times · open access
PMID 36515093 · DOI 10.1161/circulationaha.122.058794 · Animal studies
- FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway.
Journal of cellular and molecular medicine · May 5, 2022 · Animal study · cited 39 times · open access
PMID 35510614 · DOI 10.1111/jcmm.17333 · Animal studies
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: FOXO4-D-Retro-Inverso; FOXO4-DRI; Proxofim
((TITLE_ABS:"FOXO4-D-Retro-Inverso" OR CHEM:"FOXO4-D-Retro-Inverso" OR TITLE_ABS:"FOXO 4-D-Retro-Inverso" OR CHEM:"FOXO 4-D-Retro-Inverso") OR (TITLE_ABS:"FOXO4-DRI" OR CHEM:"FOXO4-DRI" OR TITLE_ABS:"FOXO 4-DRI" OR CHEM:"FOXO 4-DRI") OR (TITLE_ABS:"Proxofim" OR CHEM:"Proxofim")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). FOXO4-DRI research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/foxo4-dri